Brind.

Ongoing LNP litigation presents legal uncertainties involving Moderna, Roivant Sciences, and Pfizer.

2 reports, 2 independent Updated Aug 12

Gone quiet Reached 2 outlets in its first 24 hours

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Ongoing LNP litigation presents legal uncertainties involving Moderna, Roivant Sciences, and Pfizer.

Who's involved

What this event is mainly about

Moderna Roivant Sciences (United States)Pfizer

Keep exploring

The entities involved

Moderna
American biotechnology company
- Analyst downgrades and market challenges are impacting Moderna amid waning demand for COVID-19 vaccines, alongside pipeline successes.Mon 17:09
- Positive test results were reported for Moderna's flu vaccine.Sun 15:33
Roivant Sciences (United States)
company in New York, United States
- Ramaswamy's financial profile and business interests in Roivant Sciences are being reported amid the Ohio gubernatorial race.Wed 01:49
Pfizer
American multinational pharmaceutical and biotechnology corporation
- Dave Long trained at Fort Knox after graduating from Boardman High School and later worked for Pfizer.Mon 05:00
- MarketBeat's screener has identified a list of dividend stocks.Sun 22:22

Coverage

Newest first; wire copies grouped

Aug 12GuruFocus.comRoivant Sciences Ltd (ROIV) Q1 2025 Earnings Call Highlights: Strong Cash Position and ... Net Loss: Adjusted net loss of $170 million for the quarter. Cash Utilization: Approximately $200 million, e
Aug 11GlobeNewswireRoivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update BASEL, Switzerland and LONDON and NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq